Elise Hardy

Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial

Juan P. Frías, Cristian Guja, Elise Hardy et al. · The Lancet Diabetes & Endocrinology · 2016 · 389 citations

Medicine, Internal Medicine, Pharmacotherapy +16

Dapagliflozin Is Effective as Add-on Therapy to Sitagliptin With or Without Metformin: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

Serge Jabbour, Elise Hardy, Jennifer Sugg et al. · Diabetes Care · 2013 · 286 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial

Serge Jabbour, Juan P. Frías, Elise Hardy et al. · Diabetes Care · 2018 · 97 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Modeling effects of <scp>SGLT</scp>‐2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes

Julia Dziuba, Peter Alperin, J. Racketa et al. · Diabetes Obesity and Metabolism · 2014 · 96 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes

Amalia Gastaldelli, Enrico Repetto, Cristian Guja et al. · Diabetes Obesity and Metabolism · 2019 · 81 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17